| scholarly article | Q13442814 |
| P356 | DOI | 10.1067/MAI.2002.121949 |
| P698 | PubMed publication ID | 11842297 |
| P50 | author | Ulrich Wahn | Q92562656 |
| P2093 | author name string | Joachim Kuehr | |
| Wolfgang Leupold | |||
| Stefan Zielen | |||
| Karl-Christian Bergmann | |||
| Wolfgang Kamin | |||
| Uwe Schauer | |||
| Claudia Rolinck-Werninghaus | |||
| Andrea Von Berg | |||
| Thomas Hultsch | |||
| Jens Brauburger | |||
| Michael Gräve | |||
| P433 | issue | 2 | |
| P921 | main subject | allergic rhinitis | Q272436 |
| immunotherapy | Q1427096 | ||
| seasonal allergic rhinitis | Q3740609 | ||
| P304 | page(s) | 274-280 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis | |
| P478 | volume | 109 |
| Q35141146 | A randomised multicentre trial of acupuncture in patients with seasonal allergic rhinitis--trial intervention including physician and treatment characteristics |
| Q36642971 | A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma |
| Q35427205 | Actual therapeutic management of allergic and hyperreactive nasal disorders |
| Q42925724 | Acupuncture research in the era of comparative effectiveness research |
| Q40812061 | Advances in anti-IgE therapy |
| Q36411170 | Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses |
| Q37860985 | Allergen-specific immunotherapy in atopic eczema |
| Q26739254 | Allergen-specific immunotherapy in pediatric allergic asthma |
| Q35875669 | Allergic rhinitis in children : diagnosis and management strategies |
| Q64116508 | An External CAM Therapy (Tian Jiu) versus Placebo in Treatment of Allergic Rhinitis: A Pilot Single-Blinded, Three-Arm, Randomized Controlled Study |
| Q47146658 | An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases. |
| Q38252958 | An overview of the effects of anti-IgE therapies |
| Q88524865 | Anaphylaxis secondary to Parietaria judaica (wall pellitory) |
| Q24606957 | Anaphylaxis: a history with emphasis on food allergy |
| Q42091038 | Anti-IgE Treatment for Disorders Other Than Asthma |
| Q28294789 | Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases |
| Q37802158 | Anti-IgE in the treatment of allergic disorders in pediatrics |
| Q36834564 | Anti-immunoglobulin e therapy |
| Q35546007 | Asthma and rhinosinusitis |
| Q34725718 | BSACI guidelines for the management of allergic and non-allergic rhinitis |
| Q38109694 | Chapter 17: Immunomodulation of allergic sinonasal disease |
| Q36647136 | Childhood asthma: breakthroughs and challenges |
| Q37822834 | Clinical immunology review series: an approach to desensitization |
| Q80843158 | Control of allergic reactions in mice by an active anti-murine IL-4 immunization |
| Q64241041 | Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease |
| Q40119246 | Current and future applications of the anti-IgE antibody omalizumab |
| Q37427490 | Current immunological approaches for management of allergic rhinitis and bronchial asthma |
| Q38296706 | Developing therapies for peanut allergy |
| Q80013148 | Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients |
| Q47729425 | Efficacy of chlorophyll c2 for seasonal allergic rhinitis: single-center double-blind randomized control trial. |
| Q37726651 | Emerging therapies for food allergy. |
| Q39434071 | Endotype-driven treatment in chronic upper airway diseases. |
| Q34929214 | From IgE to anti-IgE: where do we stand? |
| Q24630319 | Future therapies for food allergies |
| Q36834323 | Halting the allergic march |
| Q37554168 | IgE-Related Chronic Diseases and Anti-IgE-Based Treatments |
| Q35685195 | Immunological mechanisms in specific immunotherapy. |
| Q39244341 | Immunotherapy - Vaccines for allergic diseases |
| Q38352179 | Immunotherapy in all aspects |
| Q35970684 | Immunotherapy in the age of anti-IgE. |
| Q38703485 | Induction of Bronchial Tolerance After 1 Cycle of Monophosphoryl-A-Adjuvanted Specific Immunotherapy in Children With Grass Pollen Allergies |
| Q35674150 | Innovative therapies for asthma: anti-IgE -- the future? |
| Q36561222 | Interleukin-10-secreting regulatory T cells in allergy and asthma |
| Q49025332 | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis |
| Q35581744 | Is there a role for anti-IgE in combination with specific allergen immunotherapy? |
| Q37807554 | Mechanisms of immunotherapy: a historical perspective |
| Q35605442 | New targets for allergic rhinitis--a disease of civilization |
| Q37304734 | New types of immunotherapy in children. |
| Q92485491 | Novel therapeutic targets for allergic airway disease in children |
| Q38517653 | Off-Label Uses of Omalizumab. |
| Q36284896 | Omalizumab : other indications and unanswered questions |
| Q35729300 | Omalizumab and the treatment of allergic rhinitis |
| Q34623856 | Omalizumab in the management of patients with allergic (IgE-mediated) asthma |
| Q37829671 | Omalizumab: Anti-IgE therapy in allergy |
| Q36348627 | Omalizumab: a monoclonal anti-IgE antibody |
| Q38070681 | Oral immunotherapy for food allergy: towards a new horizon |
| Q73772721 | Peanut allergy: recent advances |
| Q38129766 | Pediatric allergic rhinitis and asthma: can the march be halted? |
| Q28073074 | Personalized Medicine in Allergy |
| Q36561253 | Pollen immunotherapy: selection,prevention, and future directions |
| Q36073821 | Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. |
| Q37129280 | Practice patterns of allergen immunotherapy in Korea: where are we? |
| Q81203060 | Prevention strategies for asthma--secondary prevention |
| Q35915283 | Rationale for new treatments aimed at IgE immunomodulation |
| Q36284899 | Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody |
| Q33586188 | Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children |
| Q26771289 | The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy |
| Q38021923 | The future of food allergy therapeutics |
| Q36103237 | The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis |
| Q34994970 | The use of anti-IgE in the treatment of allergic asthma |
| Q98772414 | The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: Current updates |
| Q38002411 | Therapeutic effects and biomarkers in sublingual immunotherapy: a review |
| Q37567423 | Therapeutic manipulation of immune tolerance in allergic disease |
| Q41986315 | Tian Jiu therapy for allergic rhinitis: study protocol for a randomized controlled trial |
| Q30801642 | Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review |
| Q38134468 | Update on allergen immunotherapy for treatment of allergic diseases |
| Q79327310 | Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab) |
| Q38052066 | Use of omalizumab in the treatment of food allergy and anaphylaxis |
| Q80430957 | [Past and future of allergen immunotherapy] |
| Q52726319 | [Pharmacoprophylaxis and co-medications in allergen-specific immunotherapy]. |
Search more.